SRR15030864
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.390
- MYOGENESIS+0.370
- HEDGEHOG_SIGNALING+0.340
- UV_RESPONSE_DN+0.340
- WNT_BETA_CATENIN_SIGNALING+0.300
- APICAL_JUNCTION+0.240
- ANGIOGENESIS+0.220
- TGF_BETA_SIGNALING+0.180
- INTERFERON_ALPHA_RESPONSE+0.130
- MITOTIC_SPINDLE+0.130
Top 10 suppressed
- MYC_TARGETS_V1-0.590
- OXIDATIVE_PHOSPHORYLATION-0.550
- MTORC1_SIGNALING-0.540
- E2F_TARGETS-0.490
- GLYCOLYSIS-0.450
- PROTEIN_SECRETION-0.450
- UNFOLDED_PROTEIN_RESPONSE-0.420
- MYC_TARGETS_V2-0.410
- G2M_CHECKPOINT-0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 3383d8e1-d61d-4346-a589-007ad2829e36 | — | — | 0.921 |
| 2 | SRR6013599 | — | cohortMD2 | 0.897 |
| 3 | SRR1313107 | — | F | 0.892 |
| 4 | MBCProject_2661_T2_RNA | — | A | 0.873 |
| 5 | X84315f98.9366.4174.be54.3cdd1fd9db07 | — | cohortA1 | 0.869 |
| 6 | AUR-AFE5-TTM4-A-1-1-R-A742-41 | — | D | 0.861 |
| 7 | SRR6013529 | — | cohortMD2 | 0.855 |
| 8 | TCGA-A7-A26I-01B-06R-A22O-07 | — | D | 0.850 |
| 9 | TCGA-QK-A8Z9-01B-11R-A39I-07 | — | — | 0.839 |
| 10 | a83e78c0-8b1b-4576-aace-4bee1dee5046 | — | — | 0.838 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.130 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.090 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.080 | Inavolisib | — uncovered |
| COAGULATION | 0.070 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |